The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Tirzepatide will be available at pharmacies in Ireland initially in doses of 2.5 mg and 5 mg, with availability of higher ...

The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses ... Wegovy, and Ozempic, including: Medical News Today has strict sourcing guidelines and ...

of Ozempic as of January 2025 is $998 for a one-pen set. The WAC for Victoza, by comparison, is between $545 and $851. The cost of generic Victoza can be expected to be lower. Both drugs are covered ...

Some pens use cartridges inserted into the pen ... need adjustments. Ozempic (semaglutide) is not approved for the treatment of type 1 diabetes. Ozempic is a once-weekly injection that helps lower ...

Patients testing a new weight-loss drug developed by the creators of Ozempic have revealed the extreme effects it had on their bodies. Danish pharma giant Novo Nordisk has been tight-lipped ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo ... 3 Semaglutide has been approved by the FDA in both long-acting injectable (Wegovy and Ozempic) and daily oral tablet ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.